NEWS
Our Latest News
ARCHIMED’s MED II sells DIESSE, returning 4.6x to shareholders
ARCHIMED’s MED II sells DIESSE, returning 4.6x to shareholders
Private equity healthcare specialist ARCHIMED announces the sale of DIESSE to private equity firm Fremman Capital. The transaction caps a five-year partnership with DIESSE and marks the latter’s transformation into a leading clinical diagnostics innovator. The deal returns 4.6 times invested capital to shareholders.
ARCHIMED strengthens its North American capabilities
January
26,
2021
ARCHIMED’s Direct Healthcare Group sees annual revenue more than double through four Buy-and-Build purchases over nine months
January
25,
2021
ARCHIMED’s BOMI Group enters new geographies and market segments through six Buy-and-Build acquisitions made over eight months
January
25,
2021
ARCHIMED buys Germany’s Zyto Group of Cancer Diagnostics companies in partnership with owners and management
January
12,
2021
ARCHIMED’s NAMSA announces key acquisition of Syntactx
January
5,
2021
368